Related Experiment Video
Updated: Jan 21, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics
Lydia Robinson-Garcia1, Joana Ferreira da Silva1, Joanna I Loizou2
1CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Abstract:
Kinases are signaling enzymes that regulate diverse cellular processes. As such, they are frequently mutated in cancer and therefore represent important targets for drug discovery. However, until recently, systematic approaches to identify vulnerabilities and resistances of kinases to DNA-damaging chemotherapeutics have not been possible, partially due to the lack of appropriate technologies. With the advent of CRISPR-Cas9, a comprehensive study has investigated the cellular survival of more than 300 kinase-deficient isogenic cell lines to a diverse panel of DNA-damaging agents, enriched for chemotherapeutics. Here, we discuss how this approach has allowed for the rational development of combination therapies that are aimed at using synthetic lethal interactions between kinase deficiencies and DNA-damaging agents that are used as chemotherapeutics.
Insights
This study used CRISPR-Cas9 technology to screen over 300 kinase-deficient cell lines against DNA-damaging chemotherapy agents. This identified synthetic lethal interactions for developing novel combination cancer therapies.
Area of Science:
- Molecular Biology
- Cancer Biology
- Pharmacology
Background:
- Kinases are crucial signaling enzymes regulating cellular functions.
- Kinase mutations are common in cancer, making them key drug targets.
- Systematic identification of kinase vulnerabilities to chemotherapy was previously limited.
Purpose of the Study:
- To investigate kinase dependencies and drug resistance mechanisms.
- To leverage new technologies for comprehensive kinase screening.
- To enable rational design of combination therapies.
Main Methods:
- Utilized CRISPR-Cas9 gene editing to create over 300 isogenic kinase-deficient cell lines.
- Exposed these cell lines to a diverse panel of DNA-damaging chemotherapeutic agents.
- Analyzed cellular survival to identify vulnerabilities and resistances.
Main Results:
- Identified specific kinase deficiencies that sensitize cells to DNA-damaging agents.
- Discovered synthetic lethal interactions between kinase loss and chemotherapy.
- Provided a framework for understanding drug resistance pathways.
Conclusions:
- CRISPR-Cas9 screening is a powerful tool for kinase-targeted drug discovery.
- Synthetic lethality between kinase deficiencies and chemotherapy offers new therapeutic strategies.
- This approach facilitates the rational development of combination therapies for cancer treatment.
Related Concept Videos
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
02:36DNA Damage Can Stall the Cell Cycle
02:36DNA Damage can Stall the Cell Cycle
02:41Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
02:55Synthetic Biology
Golden rice
Golden rice is a genetically modified...